ArticleCureus2025
Diagnostic Challenge of Nodal Nevi Mimicking Metastatic Melanoma in Axillary Lymph Nodes Following Neoadjuvant Therapy for Breast Cancer: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nodal nevi are benign melanocytic proliferations within lymph nodes that can closely mimic metastatic melanoma, posing a significant diagnostic challenge, particularly in breast cancer patients undergoing lymph node dissection after neoadjuvant chemotherapy. Accurate differentiation between nodal nevi and true melanoma metastases is essential to avoid misdiagnosis and overtreatment. Immunohistochemical (IHC) markers such as preferentially expressed antigen in melanoma (PRAME), p16, human melanoma black-45 (HMB-45), and Ki-67 are critical tools for diagnostic clarification. We present a diagnostically challenging case of multiple infiltrative nodal nevi in a 59-year-old female with triple-negative invasive ductal carcinoma, no special type, of the breast. The patient had a prior history of dysplastic nevus on the upper trunk and presented with a 1.5 cm palpable mass in the left breast and a 5 cm left axillary mass. Following neoadjuvant chemotherapy, both lesions demonstrated a clinical reduction in size. She subsequently underwent a partial mastectomy and axillary lymph node dissection. Histologic examination revealed no residual invasive carcinoma in the breast. However, four axillary lymph nodes contained atypical melanocytic-appearing cells in the subcapsular sinuses with extension into the nodal parenchyma, raising the differential diagnosis of residual carcinoma versus metastatic melanoma. Initial IHC showed these atypical cells to be melanocytic in origin (SOX10 and melanoma cocktail positive; AE1/AE3 negative). While initial interpretation favored metastatic melanoma, further IHC workup demonstrated low proliferative activity (Ki-67 <1%), diffuse p16 positivity, and negativity for both HMB-45 and PRAME. These findings, along with dermatopathology consultation, supported a diagnosis of multiple nodal nevi rather than melanoma. This case underscores the diagnostic pitfall posed by infiltrative nodal nevi, particularly when they mimic melanoma in the setting of breast cancer. It highlights the importance of comprehensive immunohistochemical panels, including PRAME, p16, HMB-45, and Ki-67, and the value of second opinions and dermatopathology consultation in avoiding diagnostic error.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.